Effect of the Gly972Arg, SNP43 and Pro12Ala polymorphisms of the genes IRS1, CAPN10 and PPARG2 on secondary failure to sulphonylurea and metformin in patients with type 2 diabetes in Yucatán, México;Efecto de los polimorfismos Gly972Arg del gen IRS1, SNP43 del gen CAPN10 y Pro12Ala del gen PPARG2 sobre la falla secundaria a sulfonilureas y metformina en pacientes con diabetes tipo 2 de Yucatán, México

Investigacion Clinica

Volumn 50, Issue 1, 2009, Pages 65-76

  García Escalante, María Guadalupe ^a   Suárez Solís, Víctor Manuel ^a   López Ávila, María Teresa De Jesús ^a   Pinto Escalante, Doris Del Carmen ^a   Laviada Molina, Hugo ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

Author keywords

Polymorphisms Gly972Arg of the IRS1 gene; Pro12Ala of the PPARG2 gene; SNP43 of gene CAPN10; Type 2 diabetes

Indexed keywords

ALANINE; ARGININE; CALPAIN 10; GLIBENCLAMIDE; GLYCINE; HEMOGLOBIN A1C; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; ANTIDIABETIC AGENT; CALPAIN; GLYCOSYLATED HEMOGLOBIN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ALLELE; ANTHROPOMETRY; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DNA DETERMINATION; DRUG TREATMENT FAILURE; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLISM; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CODING; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; BLOOD; DRUG RESISTANCE; GENETICS; HAPLOTYPE; MIDDLE AGED; PHYSIOLOGY; RISK;

AGED; ANTHROPOMETRY; BODY MASS INDEX; CALPAIN; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; GENOTYPE; HAPLOTYPES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RECEPTOR SUBSTRATE PROTEINS; LIPIDS; MALE; METFORMIN; MEXICO; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK; SULFONYLUREA COMPOUNDS;

EID: 67649088187     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Norma Oficial Mexicana NOM-015-SSA2-2000, Para la prevención, tratamiento y control de la diabetes.
2. Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro L, Gnasso A, Federico M, Perticone F, Lauro R, Irace C, Lauro L, Gnasso A, Federico M, Perticone F, Lauro R. The Arg972 Variant in Insulin Receptor Substrate-1 Is Associated With an Increased Risk of Secondary Failure to Sulfonylurea in Patients With Type 2 Diabetes. Diabetes Care 2004; 27:1394-1398.
3. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Ganso A, Grupillo M, Lauro R, Hribal ML, Perticone F, Marchetti P. The E23K Variant of KCNJ11 Encoding the Pancreatic β-Cell Adenosine 5′-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes. J Clin Endocrin Metab 2006; 91:2334-2339.
4. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001; 15:2099-2111.
5. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphism of insulin Receptor Substrate-1 in non-insulin-dependent diabetes mellitus. Lancet. 1993; 342:828-832.
6. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with type 2 diabetes. A meta-analysis of 27 studies. Diabetologia 2003; 46:990-995.
7. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996; 97:2569-2575.
8. McGettrick AJ, Feener EP, Kahn CR. Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J Biol Chem 2005; 280:6441-6446.
9. Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, Borboni P, Sesti G. The Gly972Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cell. J Clin Invest 1999; 104:357-364.
10. Marchetti P, Lupi R, Federici M, Marselli L, Masini M, Boggi U, Del Guerra S, Patane G, Piro S, Anello M, Bergamini E, Purrello F, Lauro R, Mosca F, Sesti G, Del Prato S. Insulin secretory function is impaired in isolated human islets carrying the Gly(972)Arg IRS-1 polymorphism. Diabetes 2002; 51:1419-1424.
11. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin therapeutic and cellular mechanisms. Drugs 1999; 58:31-39.
12. Horikawa Y. Calpain-10 (NIDDM1) as a Susceptibility Gene for Common Type 2 Diabetes. Endocr J 2006; 53:567-576.
13. Johnson JD, Han Z, Otani K, Ye H, Zhang Y, Wu H, Horikawa Y, Misler S, Bell GI, Polonsky K. RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem 2004; 279:24794-24802.
14. Marshall C, Hitman GA, Partridge CJ, Clark A, Ma H, Shearer TR, Turner MD. Evidence that an isoform of Calpain-10 is a regulator of exocytosis in pancreatic beta cells. Mol Endocrinol 2005; 19:213-224.
15. Logie LJ, Brown AE, Yeaman SJ, Walter M. Calpain inhibition and insulin action in cultured human muscle cells. Mol Genet Metab 2005; 85:54-60.
16. Paul DS, Harmon AW, Winston CP, Patel YM. Calpain facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes. Biochem J 2003; 376: 625-632.
17. Hanis CL, Boerwinkle E, Chakraborty R, Ellsworth DL, Concannon P, Stirling B, Morrison VA, Wapelhorst B, Spielman RS, Gogolin-Ewens KJ, Shepard JM, Williams SR, Risch N, Hinds D, Iwasaki N, Ogata M, Omori Y, Petzold C, Rietzch H, Schröder HE, Schulze J, Cox NJ, Menzel S, Boriraj VV, Chen X, Lim LR, Lindner T, Mereu LE, Wang YQ, Xiang K, Yamagata K, Yang Y, Bell GI. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 1996; 13:161-166.
18. Horikawa Y, Oda N, Imamura S, Fujiwara, Makino M, Seino Y, Itoh M, Takeda J. Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese. J Clin Endocrinol Metab 2003; 88:244-247.
19. Horikawa Y, Oda N, Cox N, Xiangquan L, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz P, del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze J, Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26:163-175.
20. Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, Shen GQ, Mott D, Knowler WC, Cox NJ, Horikawa Y, Oda N, Bell GI, Bogardus C. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000; 106: R69-73.
21. Stumvoll M, Fritsche A, Madaus A, Stefan N, Weisser M, Machicao F, Häring H. Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans. Diabetes 2001; 50:2161-2163.
22. López-Orduña E, García-Mena J, García-Macedo R, Stumvoll M, Cruz M. CAPN10 mRNA splicing and decay is not affected by a SNP associated with susceptibility to type 2 diabetes. Biochem Biophys Res Commun 2007, 358:831-836.
23. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPARgamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241:270-274.
24. Stumvoll M, Häring H. The peroxime proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002; 51:2341-2347.
25. Stefan N, Fritsche A, Häring H, Stumvoll M. Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene. Diabetes 2001; 50:1143-1148.
26. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003; 65:261-311.
27. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M. The Pro12 Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001; 50:891-894.
28. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 2005; 280:23653-23659.
29. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rücker C. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol 2007; 71:398-406.
30. Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelón-Hernandez G, Sánchez-Castillo C, Attie F, Tapia-Conyer R. Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Final outcomes from the National Health Survey 2000. Arch Cardiol Mex 2003; 73:62-77.
31. Miller SA, Dijkes DD, Polesky HF A simple salting out procedure for extracting DNA from nucleated cell. Nuclei Acid Res 1988, 16:1215-1218.
32. Carlsson E, Fredriksson J, Groop L, Ridderstrale M. Variation in the Calpain-10 Gene Is Associated with Elevated Triglyceride Levels and Reduced Adipose Tissue Messenger Ribonucleic Acid Expression in Obese Swedish Subjects. J Clin Endocrinol Metab 2004; 89: 3601-3605.
33. Pihlajamäki J, Salmenniemi U, Vänttinen M, Ruotsalainen E, Kuusisto J, Vauhkonen I, Kainulainen S, Ng MC, Cox NJ, Bell GI, Laakso M. Common polymorphisms of calpain-10 are associated with abdominal obesity in subjects at high risk of type 2 diabetes. Diabetologia 2006; 49:1560-1566.
34. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-287.
35. Lindi VI, Uusitupa MI, Lindström J, Louheranta A, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Tuomilehto J. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish diabetes prevention study. Diabetes 2002; 51:2581-2586.
36. García-Fajardo LV, García-Mena J, Wacher-Rodarte N, de la Vega F, Kumate J, Cruz-López M. Asociación de polimorfismos de una sola base (snps) en genes candidatos CAPN10, IRS-1 Y PPAR-G con diabetes tipo 2 en una muestra de población mexicana. Memorias del XXVI Congreso Nacional de la Sociedad Mexicana de Bioquímica A.C. Guanajuato, Guanajuato. 12 al 17 de noviembre, 2006.
37. del Bosque-Plata L, Aguilar-Salinas C, Tusié-Luna M, Ramírez-Jiménez S, Rodrígues-Torres M, Aurón- Gómez M, Ramirez E, Velasco-Perez ML, Ramirez-Silva A, Gomez-Perez F, Hanis CL, Tsuchiya T, Yoshiuchi I, Cox NJ, Bell GI. Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population. Mol Genet and Metab 2004; 81(2): 122-126.
38. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31:Suppl 1:S12-54.
39. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15:297-303.
40. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 2007; 117:1226-1229.